Comment on: Evaluation of early biomarkers of renal dysfunction in diabetic patients

References

1. ↵
   1. Al-Hazmi SF,
   2. Gad HG,
   3. Alamoudi AA,
   4. Eldakhakhny BM,
   5. Binmahfoozv SK,
   6. Alhozali AM

   (2020) Evaluation of early biomarkers of renal dysfunction in diabetic patients. Saudi Med J 41:690–697.

   OpenUrlAbstract/FREE Full Text
2. ↵
   1. Afkarian M,
   2. Sachs MC,
   3. Kestenbaum B,
   4. Hirsch IB,
   5. Tuttle KI,
   6. Himmelfarb J,
   7. et al.

   (2013) Kidney disease and increased mortality risk in type 2 Diabetes. J Am Soc Nephrol 24:302–308.

   OpenUrlAbstract/FREE Full Text
3. ↵
   1. Bentata Y,
   2. Haddiya I,
   3. Latrech H,
   4. Serraj K

   (2013) Progression of diabetic nephropathy, risk of end-stage renal disease and mortality in patients with type-1 diabetes. Saudi J Kidney Dis Transpl 24:392–402.

   OpenUrlPubMed
4. ↵
   1. Siddiqi Z,
   2. Karoli R,
   3. Kaul A,
   4. Fatima J,
   5. Varshney S,
   6. Beg MS

   (2017) Evaluation of neutrophil gelatinase-associated lipocalin and cystatin C as early markers of diabetic nephropathy. Ann Afr Med 16:101–106.

   OpenUrl
5. ↵
   1. Chena B,
   2. Lib Y,
   3. Liua Y,
   4. Zanga C,
   5. Wua M,
   6. Xu Z

   (2019) Diagnostic value of neutrophil gelatinase-associated lipocalin in diabetic nephropathy:a meta-analysis. Renal Failure 41:489–496.

   OpenUrl